Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Genstar Capital is buying out clinical research company PRA International for $744.8 million.
Subscribe to our email newsletter
The entire transaction is valued at about $790 million, comprised of the 24.4 million company shares that were outstanding as of April 28 as well as $30.50 each shares (totalling $744.8 million).
PRA said the acquisition was approved by its board of directors. The purchase agreement is based on a 13% premium on its closing share price on July 24.
Genstar originally owned PRA before the company went public in 2004, and currently has a 12.8% holding in the company.
The transaction is expected to be completed in the fourth quarter.
PRA, which has 2700 employees, conducts clinical trials in therapeutic areas with a special emphasis in the areas of oncology, central nervous system, allergy and respiratory and cardiovascular disorders.